SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: squetch who wrote (9928)10/21/1997 4:08:00 PM
From: Andrew H  Respond to of 32384
 
That would make a lot of sense, stan since LGND is already working on CTCL, but this wasn't one which Henry mentioned. He wouldn't be trying to lead us astray, would he? (:>) Market for CTCL is fairly small, though. However, if they are developing with SRGN, it seems less likely.

Care to comment, Henry?? Let's check out the one Henry suggested.



To: squetch who wrote (9928)10/30/1997 2:16:00 PM
From: Henry Niman  Read Replies (2) | Respond to of 32384
 
Stan, I think that your guess on the DAB-fusion protein may be a good one. I looked up SRGN, and there is much overlap with LGND (targeting CTCL and psoriasis). DAB uses IL-2 (which LGND has licensed from CHIR in Canada) and EGF sends signals through STATs. I think that SRGN is just about out of money and could be bought for $10-$15 million. Do you know when approval for DAB is expected?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News